Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:3/4/2015)... , March 4, 2015  The strongest ... market is the increasing elderly population, according to ... recent report from the healthcare market research publisher, ... coupled with other risk factors such as obesity ... worldwide. Demand for innovative product designs and the ...
(Date:3/4/2015)... 4, 2015 GSI Group Inc. (NASDAQ: ... global leader and supplier of precision photonics and motion ... advanced industrial technology markets, today reported financial results for ... noted, all financial results in this press release are ... QuarterDuring the fourth quarter of 2014, GSI generated revenue ...
(Date:3/4/2015)... OAKS, Calif. , March 4, 2015 ... Board of Directors today declared a $0.79 per share ... will be paid on June 5, 2015, to all ... on May 14, 2015.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 16GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 17GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 18GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 19GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 20GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 21GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 23GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 24GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 25GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 26GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 27GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 28GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 29GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 30GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 31GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 32GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 33Amgen Announces 2015 Second Quarter Dividend 2
... 2, 2010 Architects and designers who visit ... HEALTHCARE DESIGN.10 exhibit next week will have ... materials can help create healthier, more sustainable healing ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090401/DC92292LOGO-b ) ...
... 2, 2010 CVS Caremark reiterated the company,s support ... regulations necessary to approve biogeneric drugs under the Affordable ... Pharmacy Operations, Scott Reid, testified before the FDA today ... an approval pathway for biosimilar and interchangeable biological products ...
Cached Medicine Technology:GREENGUARD's First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently 2GREENGUARD's First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently 3CVS Caremark Reiterates Support for FDA Implementation of Approval Pathway for Biogeneric Drugs 2
(Date:3/4/2015)... March 04, 2015 Vancouver chiropractic ... received two awards in the prestigious Vancouver Courier ... February 27, 2015. The company secured third place ... in the “Best Registered Massage Therapist” category. ... newspapers in Canada, The Vancouver Courier is a ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 State officials ... of the School of Public Health at Georgia State ... funds were awarded by Georgia’s Division of Family and ... support the DFCS Call Center. , The 1-800-CHILDREN ... by providing information and referral services that promote the ...
(Date:3/4/2015)... 04, 2015 The popular all-natural supplement ... new L-Style Revolution™ Program. The customized program provides a ... of all health and fitness levels to follow and ... than traditional methods. , “We’re really proud to announce ... based on award winning techniques to help people according ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The bustling ... and suffers from the potential threat of Kratom. In a ... revealed that Kratom is a “drug of concern.” Although Kratom ... herb from Southeast Asia acts as a stimulant in low ... foments symptoms similar to heroin withdrawal, and includes tremors, irritation, ...
(Date:3/4/2015)... Vancouver, BC (PRWEB) March 04, 2015 ... Research , millions of people in the U.S. suffer ... acid reflux. Medications are commonly prescribed to control acid ... invasive surgical procedures can overly correct the problem and ... A Market Opportunity, GERD occurs when the lower esophageal ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3
... 16 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI) a ... development of drug products delivered to and through the ... today announced that it has entered into a license ... Covidien (NYSE: COV ), a leading global provider ...
... Argentina, June 16 Most hospitals in Latin America reveal ... radiology departments - a reason to consider the process of ... arises a need to focus on awareness as a means ... digital radiography (DR). , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ...
... ... , ... June 16, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... Benefit Perspectives survey (video) , which delineates employers, positions and opinions on ...
... ... of information on pulmonary hypertension medications and the financial help available for those ... ... its Web site tailored for those with pulmonary hypertension . The page is a ...
... Congressional committees begin to hone in on the details of ... health tracking poll finds remarkable stability in public opinion on ... the American people (61%) continue to believe that health reform ... sizeable majorities support key elements of reform currently being debated ...
... Two Organizations Will Serve a Wide Range of LGBT Youth, ... , LOS ANGELES, June 15 Uniting two leading ... a program of the L.A. Gay & Lesbian Center, announced ... Executive Officer Lorri L. Jean, at LifeWorks, annual Life Out ...
Cached Medicine News:Health News:Nuvo Research and Covidien sign U.S. license and development agreement for Pennsaid(R) and Pennsaid Plus(R) 2Health News:Nuvo Research and Covidien sign U.S. license and development agreement for Pennsaid(R) and Pennsaid Plus(R) 3Health News:The Latin American Digital Radiography Market to Grow Significantly due to the Need to Improve Digital Adoption, Observes Frost & Sullivan 2Health News:The Latin American Digital Radiography Market to Grow Significantly due to the Need to Improve Digital Adoption, Observes Frost & Sullivan 3Health News:Employees Increasingly Accept and Understand Reductions in Health Plan Benefits and Premium-Cost Sharing 2Health News:Employees Increasingly Accept and Understand Reductions in Health Plan Benefits and Premium-Cost Sharing 3Health News:New Source of Information on Pulmonary Hypertension Medications 2Health News:Public Opinion on Health Reform Stable and Supportive as Debate Heats Up, But Moveable Too 2Health News:Public Opinion on Health Reform Stable and Supportive as Debate Heats Up, But Moveable Too 3Health News:Public Opinion on Health Reform Stable and Supportive as Debate Heats Up, But Moveable Too 4Health News:LifeWorks Mentoring to Become Program of L.A. Gay & Lesbian Center 2Health News:LifeWorks Mentoring to Become Program of L.A. Gay & Lesbian Center 3
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... panels mounted on powder-coated steel ... free-standing modular cleanroom that meets ... Optional ceiling HEPA filter/fan units, ... to customer requirements. Negative-pressure ventilation, ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: